Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Univercells granted 2.4M ($2.9M) to Develop Antibody Production Platform

publication date: Feb 7, 2018
 | 
author/source: Univercells

univercellsFunding from the Walloon Region will enable Univercells to initiate a development program aimed at driving down costs of biosimilars manufacturing

Univercells SA, a technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions, today announces that it has received a grant  from the Walloon Region. Pierre-Yves Jeholet, vice president and minister of economic affairs, industry, research, innovation, digital, employment and training in the Walloon government granted the company €2.4M ($2.9M). This funding will enable the company to launch a program aimed at developing its innovative protein platform, paving the way for the cost-effective production of biosimilars. The platform will enable production units to be deployed anywhere in the world, providing access to high-quality biologics independent of location.

The new generation of biologic medicines represents significant progress in healthcare, successfully addressing oncology, auto-immune and rare diseases. However, their prohibitive costs and limited supply lead to unequal access around the world, preventing wide coverage.

The increasing demand for affordable biologics calls for adapted production capacities, capable of drastic cost containment for a significant impact on the commercial price.

Univercells’ new program will focus on designing the next generation of production technologies, drastically reducing manufacturing costs while delivering large quantities, answering the growing demand for antibodies. The resulting low-footprint high-capacity production units are more affordable to build and operate, improving worldwide access to high-quality biologics.

“We are very appreciative of the continuing insight and support from Wallonia,” said Hugues Bultot, co-founder and CEO of Univercells. “The region has supported Univercells since its early days, with a successful earlier project leading to the commercial development of our vaccine micro-facility. We are confident this second platform will demonstrate the same favorable outcome and aid in fostering access to healthcare worldwide.”

Last December, Univercells announced the successful closing of a €3 million ($3.56M) capital increase in a Series-A equity financing round, led by private investors. Prior to that the company received a $12 million grant from the Bill & Melinda Gates Foundation and  €3 million from Takeda in 2015.


more about univercells


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events